An interventional study of Fluoxetine and Placebo in Depression - Major Depressive Disorder, Irritability and Depression, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by University of Oxford · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.
Among the 43 studies testing fluoxetine in Depression, this one is the 24th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 10 with no phase, and was the 41st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:
University of Bern · Sites in Zimbabwe
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Federal University of Latin American Integration · Sites in Brazil
Ages 25–65 · Healthy volunteers
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 13–18
By country, each count listing its studies:
Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 24 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 9 · Phase 4 9
First in 1995; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 97 across the 42 interventional studies. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 43 have an industry lead sponsor. The 10 most frequent:
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
41 studies in Depression by University of Oxford: 12 open now, 12 under way, none of them phase 3. Of 22 finished, 0 (0%) have results posted.
Among the 41 studies in Depression by University of Oxford, this one is the 17th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2025, is one of 33 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 36th registered.
University of Oxford’s Depression studies by the year they started, since 2004.
6 of the studies testing fluoxetine in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424781University of OxfordFluoxetine on Emotional Experience (FLEX) Study | 2026-12-31 |
| NCT05814640First Affiliated Hospital of Chongqing Medical UniversitySequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) | 2026-12-31 |
| NCT05976347Wake Forest University Health SciencesIdentifying and Treating Depression in the Orthopaedic Trauma Population | 2027-05 |
| NCT07456501University of OxfordFluoxetine and Understanding Social Experiences | 2027-07-20 |
| NCT07110831University of IbadanDisposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies testing fluoxetine in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among University of Oxford’s 41 in Depression:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical medicine study is to investigate how does antidepressant fluoxetine modulate anger processing in healthy young people . The main questions it aims is to answer are:
Researchers will compare fluoxetine to a placebo to see if drug fluoxetine affects anger processing.
Participants will:
Take 20mg fluoxetine or a placebo every day for 7 days. Visit the university site for questionnaire and tasks assessments. Heart rate variability and facial expressions will be recorded in some of the tasks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The participant may not enter the study if ANY of the following apply:
Psychiatric History:
Lifestyle:
Physical Health:
Medical History:
Prior Study Participation:
Others
•Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's ability to participate in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be taking 20mg fluoxetine daily.
Drug: Fluoxetine
Participants will be taking one placebo capsule daily.
Drug: Placebo
Participants will receive 20mg of fluoxetine daily for 7 days. Tablets encapsulated to aid blinding.
Participants will receive one dose placebo (sucrose) daily for 7 days. Tablets encapsulated to aid blinding.
Behavioral Measure: Facial Expression Recognition Task (FERT)
Recognition of angry faces in the Facial Expression Recognition Task
Time frame: On the last day of the 7-day treatment
Behavioural Measure: The Affordances Task
Performance on an affordances task in which participants have to decide to fight or escape under threatening situations with different environmental affordance conditions.
Time frame: On the last day of the 7-day treatment
Behavioural Measure: Emotional Categorization Task (ECAT)
Performance on recognising and memorising anger related words in the Emotional Categorization Task (ECAT)
Time frame: On the last day of the 7-day treatment.
Performance on Carnival Task
Performance on an anger induction task in which the study's rigged design creates frustrating non-reward responses.
Time frame: On the last day of the 7-day treatment.
Subjective Measure: Rest Task
Participants' rating of anger-related emotions during a resting task.
Time frame: On the last day of the 7-day treatment.
Subjective Measure: Anger Memory Recall Task
Participants' ratings of anger-related emotions and bodily sensations during a task that involves guided imagery of a past personal experience.
Time frame: On the last day of the 7-day treatment.
Physiological Measure: Heart Rate Variability
Heart rate variability measures across a battery of anger-induction tasks.
Time frame: On the last day of the 7-day treatment.
Physiological Measure: Facial Expression
Video recordings that identify facial expressions across a battery of anger-induction tasks.
Time frame: On the last day of the 7-day treatment.
Behavioural measure: Emotional Recognition Memory Task (EMEM)
Description: Performance on recognising and memorising anger related words in the Emotional Recognition Memory Task (EMEM).
Time frame: On the last day of the 7-day treatment.
Plan to share: Yes — Data which has been fully de-identified and relevant supporting materials (e.g., study protocol, data dictionary, and analysis documentation) may be shared with other academic organisations in the future, including those outside of the UK and the EU. Participants will be informed of this and specific consent to this is obtained within the Informed Consent Form.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will be available in a few months after all data has been completed (ETA Oct 2026), unblinding has occurred (ETA Dec 2026), and all data analyses has been completed (Dec 2027).
Access criteria: Fully de-identified individual participant data (IPD) and relevant supporting documentation may be shared with academic researchers for scientific research purposes. Access will be limited to researchers affiliated with recognised academic or research institutions, including those outside of the UK and EU. Approved researchers will be granted access only to fully de-identified IPD and relevant supporting materials. Data will be shared via secure transfer methods or through a controlled-access data repository.
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 14 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluoxetine